Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

1. Cabrero, M.
2. López-Corral, L.
3. Jarque, I.
4. de la Cruz-Vicente, F.
5. Pérez- López, E.
6. Valcárcel, D.
7. Sanz, J.
8. Espigado, I.
9. Ortí, G.
10. Martín- Calvo, C.
11. de la Serna, J.
12. Caballero, D.